Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2553Triple Negative Breast Neoplasms 436Carcinoma, Non-Small-Cell Lung 339Ovarian Neoplasms 315Neoplasms 282Neoplasm Metastasis 254Colorectal Neoplasms 246Stomach Neoplasms 202Pancreatic Neoplasms 196Prostatic Neoplasms 188Lung Neoplasms 180Melanoma 171Squamous Cell Carcinoma of Head and Neck 140Endometrial Neoplasms 140Head and Neck Neoplasms 124Carcinoma, Renal Cell 118Uterine Cervical Neoplasms 104Esophageal Neoplasms 97Urinary Bladder Neoplasms 92Small Cell Lung Carcinoma 87Sarcoma 85Colonic Neoplasms 80Carcinoma, Hepatocellular 62Carcinoma, Transitional Cell 61Kidney Neoplasms 51Advanced Breast Cancer 51Cholangiocarcinoma 50Liver Neoplasms 47Brain Neoplasms 43Mesothelioma 37

Interventions

ribociclib 1LSZ102 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced or Metastatic ER+ Breast Cancer × Breast × Clear all
NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Novartis

Phase 1 Terminated
199 enrolled
Breast

Advanced or Metastatic ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡